- Home
- SRG vs IKT Comparison
SRG vs IKT Comparison
Compare SRG & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRG
- IKT
- Stock Information
- Founded
- SRG 2014
- IKT 2008
- Country
- SRG United States
- IKT United States
- Employees
- SRG N/A
- IKT N/A
- Industry
- SRG Real Estate Investment Trusts
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- SRG Real Estate
- IKT Health Care
- Exchange
- SRG Nasdaq
- IKT Nasdaq
- Market Cap
- SRG 163.3M
- IKT 139.0M
- IPO Year
- SRG 2015
- IKT 2020
- Fundamental
- Price
- SRG $2.82
- IKT $2.01
- Analyst Decision
- SRG
- IKT Buy
- Analyst Count
- SRG 0
- IKT 2
- Target Price
- SRG N/A
- IKT $8.00
- AVG Volume (30 Days)
- SRG 122.6K
- IKT 123.6K
- Earning Date
- SRG 05-15-2025
- IKT 05-14-2025
- Dividend Yield
- SRG N/A
- IKT N/A
- EPS Growth
- SRG N/A
- IKT N/A
- EPS
- SRG N/A
- IKT N/A
- Revenue
- SRG N/A
- IKT N/A
- Revenue This Year
- SRG N/A
- IKT N/A
- Revenue Next Year
- SRG N/A
- IKT N/A
- P/E Ratio
- SRG N/A
- IKT N/A
- Revenue Growth
- SRG N/A
- IKT N/A
- 52 Week Low
- SRG $2.43
- IKT $1.12
- 52 Week High
- SRG $5.52
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- SRG 42.26
- IKT 49.69
- Support Level
- SRG $2.81
- IKT $1.70
- Resistance Level
- SRG $2.99
- IKT $2.12
- Average True Range (ATR)
- SRG 0.09
- IKT 0.19
- MACD
- SRG -0.00
- IKT 0.01
- Stochastic Oscillator
- SRG 11.54
- IKT 54.39
About SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, and leasing of diversified and mixed-use properties throughout the United States.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.